Savara (SVRA) Change in Acquisitions & Divestments (2018 - 2026)
Savara's (SVRA) quarterly Change in Acquisitions & Divestments came in at $13.1 million in Q1 2026, down 70.42% year-on-year from $44.4 million in Q1 2025, and up 108.84% on a QoQ basis from -$148.5 million in Q4 2025.
Savara (SVRA) Change in Acquisitions & Divestments (2018 - 2026) Analysis & Trends
Savara (SVRA) has 9 years of Change in Acquisitions & Divestments data on file, last reported at $13.1 million in Q1 2026.
- On a quarterly basis, Change in Acquisitions & Divestments fell 70.42% year-over-year to $13.1 million in Q1 2026; TTM through Mar 2026 was -$27.0 million, a 116.07% decrease from a year earlier, with the FY2025 full-year figure at $4.3 million, down 97.41% from the prior year.
- Change in Acquisitions & Divestments for Q1 2026 stood at $13.1 million, up from -$148.5 million in the prior quarter.
- Over the last five years, Change in Acquisitions & Divestments for SVRA reached as high as $119.5 million in Q4 2022 and fell as low as -$148.5 million in Q4 2025.
- Historically, Change in Acquisitions & Divestments has averaged $30.0 million across 5 years, with a median of $40.6 million in 2024.
- Across the five-year window, Change in Acquisitions & Divestments soared 300.3% in 2022 and plunged 397.34% in 2025, its largest moves.
- Year by year, Change in Acquisitions & Divestments stood at $119.5 million in 2022, then plunged by 62.01% to $45.4 million in 2023, then gained by 10.02% to $49.9 million in 2024, then plunged by 397.34% to -$148.5 million in 2025, then surged by 108.84% to $13.1 million in 2026.
- Per Business Quant data, the three most recent Change in Acquisitions & Divestments figures were $13.1 million in Q1 2026, -$148.5 million in Q4 2025, and $44.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.13 Mn |
| Mar 31, 2026 | 13.13 Mn |
| Dec 31, 2025 | -148.52 Mn |
| Dec 31, 2025 | -148.52 Mn |
| Sep 30, 2025 | 44.40 Mn |
| Sep 30, 2025 | 44.40 Mn |
| Jun 30, 2025 | 64.00 Mn |
| Jun 30, 2025 | 64.00 Mn |
| Mar 31, 2025 | 44.40 Mn |
| Mar 31, 2025 | 44.40 Mn |
| Dec 31, 2024 | 49.95 Mn |
| Dec 31, 2024 | 49.95 Mn |
| Sep 30, 2024 | 40.55 Mn |
| Sep 30, 2024 | 40.55 Mn |
| Jun 30, 2024 | 33.00 Mn |
| Jun 30, 2024 | 33.00 Mn |
| Mar 31, 2024 | 41.50 Mn |
| Mar 31, 2024 | 41.50 Mn |
| Dec 31, 2023 | 45.40 Mn |
| Dec 31, 2023 | 45.40 Mn |